Category Archives: R&D

BMS to Push Innovation in US Universities

Bristol-Myers Squibb (BMS) andĀ Allied Minds haveĀ formed Allied-Bristol Life Sciences LLC, a new enterprise to identify and foster research and preclinical development of biopharmaceutical innovations from leading university research institutions across the US. Allied-Bristol Life Sciences will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development and, ultimately, […]
Posted in R&D | Tagged , , | Leave a comment

Risk and Innovation in Biopharma: A CEO’s Perspective

In this Applied Clinical Trials article, Kadmon CEO Dr. Sam Waksal talks about the importance of imagination for innovation, current business risks in biopharma, and applying understanding to the concept of Big Data. Click here for the article.
Also posted in Biotech, Guest Blog, leadership, Strategy | Tagged , | Leave a comment

Big Data in the Pharma R&D Landscape

Big Data and the mindset that comes with it will have a fundamental impact on how pharmaceutical research will be conducted in the future, writes Peter Tormay. Innovation is the corner stone of the pharmaceutical industry. Unfortunately, the industry as a whole is not very good at it. For the last two decades the approval […]
Also posted in Guest Blog, Strategy, Technology | Tagged , , | Leave a comment

Rebranding Risk-Based Monitoring in Clinical R&D

With all of the buzz and excitement around risk-based monitoring (RBM), one might expect that the broad adoption of this emerging clinical research paradigm is well underway. Those familiar with the often painfully slow pace of innovation in the area of clinical R&D, however, will not be surprised by the more sobering reality that only […]
Posted in R&D | Tagged , , | Leave a comment

Sanofi Reports Progress Toward First Dengue Vaccine

Sanofi Pasteur, the vaccines division of Sanofi, reports that results of an efficacy study is a step closer to making dengue the next vaccine-preventable disease. Sanofi points to The Lancet’s published results showing the overall efficacy of the drug maker’s vaccine against symptomatic dengue in 56.5% in children aged 2 to 14 years old after […]
Also posted in Europe | Tagged , , , , | Leave a comment
  • Categories

  • Meta